Tuberous sclerosis complex (TSC) is an autosomal dominant, multisystem disorder characterized by the formation of hamartomas in multiple organ systems, most commonly the brain, skin, kidney, and eye. 1 Incidence of TSC is estimated to be 1 in 6000. 2, 3 TSC can be caused by mutations in either of 2 tumor-suppressor genes, TSC1 or TSC2, 4 although mutations cannot be identified in ϳ15% of cases. In up to two-thirds of patients there is no parental history of TSC, which signifies a high rate of spontaneous mutation. 5 Phenotype is highly variable, even among patients with identical mutations. 6 Diagnosis of TSC may be difficult because no single symptom is present in all patients, and none are absolutely pathognomonic. 7 Currently, clinical criteria defined by the Tuberous Sclerosis Consensus Conference in 1998 are used to diagnose TSC (Table 1) . 8 Definite TSC is diagnosed when either 2 major features or 1 major and 2 minor features are present.
Neurologic manifestations of TSC were first described by D. M. Bourneville in 1880, and were later associated with clinical signs by H. Vogt in 1908. Vogt described what is commonly known as the "classic triad" of symptoms in TSC: seizures; mental retardation; and adenoma sebaceum (angiofibromas). 9 However, studies have demonstrated that the triad occurs in only 29% of patients with TSC, and 6% lack all 3 symptoms. 10 Some presentations of TSC, such as neonatal infantile spasms with hypopigmented macules, are widely recognizable and frequently lead to diagnosis. 11 However, some features of TSC remain entirely asymptomatic, 7 such as bone lesions; whereas others appear, grow, and regress over time, 12, 13 such as cardiac rhabdomyomas and renal cysts, which reduce the likelihood of detection and diagnosis. This is particularly important in mildly affected children because many cerebral and dermatologic features of TSC may not be present or readily apparent in early life. 11 Many patients with TSC are not diagnosed until adulthood. It is not uncommon for a parent to be diagnosed only after the birth of a more severely affected child. 14 Manifestations of TSC, including seizures, 15 subependymal giant cell tumor (SGCT), 16 renal failure, 17 and lymphangioleiomyomatosis 14 can contribute to morbidity and mortality. However, many of these health risks can be minimized by early diagnosis of TSC, lifelong monitoring, and proactive treatment. 10 We examined age at diagnosis, presenting symptoms, and missed earlier signs in 243 patients with TSC. Our aim was to elucidate the role of diagnosis in the natural history of TSC. Approximately half of the patients seen at the Herscot Center are adults, and not all meet clinical criteria for TSC. Although the Herscot Center is managed by a pediatric neurologist, referred patients with suspected TSC may have any symptoms or signs of TSC. Therefore, patients with TSC who were seen at the Herscot Center are representative of all patients with TSC. Patients were excluded from the study if there were no available data for age at diagnosis or presenting symptoms or signs.
PATIENTS AND METHODS
The presenting symptom or sign was defined as the first symptom or sign to cause suspicion for TSC and lead to diagnosis. If there were 2 or more simultaneous presenting symptoms or signs, they were all counted. Infantile spasms, new onset of seizures, and a history of seizures were differentiated as separate presenting symptoms. History of seizures was defined as seizure onset occurring at least 6 months before TSC diagnosis. Earlier missed symptoms or signs were defined as symptoms or signs of TSC that were 
RESULTS
There were 243 records that contained information sufficient for inclusion. Presenting symptoms and signs varied with age (Table 2 ). Patients were diagnosed with TSC at various stages of life (Fig 1) . Patients' age at diagnosis ranged from birth to 73 years. The average age at diagnosis was 7.5 years, and median was 1 year. Patients were most likely to be diagnosed during the first 6 months of 20 (63) 1 (3) 8 (25) 1 ( (24) 1 (2) 1 (2)
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Numbers in the presenting-symptom columns will not add up to the total numbers of patients in each age group because many patients had more than 1 presenting symptom, and all presenting symptoms were counted. 
FIGURE 1
Age at diagnosis of TSC. Prenatal is defined as 0 to 1 week; early infancy, 1 week to 6 months; late infancy, 6 months to 1 year; early childhood, 1 to 5 years; late childhood, 6 to 10 years; adolescence, 11 to 20 years; and adulthood, 21 years and older.
life. There were 197 (81%) patients diagnosed before the age of 10. Diagnosis during adolescence and adulthood was not uncommon.
Genotype
There were 199 (82%) patients who underwent genetic mutational analysis, and 198 results were available for inclusion in this study (Table 3) . Patients with a TSC2 mutation were diagnosed, on average, 9 years before those with TSC1 mutations, and 11 years before those without identifiable mutations. Presenting symptoms and signs varied by genotype (Table 4) .
Presenting Symptoms
Prenatal: 0 to 1 Week Cases of earlier missed symptoms or signs included 3 with suspected developmental delay, 2 with hypopigmented macules, 3 with history of infantile spasms, and 1 whose seizures were noted only in hindsight. In 2 cases of infantile spasms and 3 cases of seizures, TSC diagnosis was delayed for undocumented reasons. In another case of onset of infantile spasms at the age of 3 months, the spasms were initially thought to be behavioral or related to milk formula. TSC was not diagnosed until the age of 9 months because of hypopigmented macules and calcifications seen on brain MRI. One infant was treated pharmacologically for hypertension during the neonatal period before renal cysts were detected at the age of 5 months.
Early Childhood: 1 to 5 Years
There were 51 patients (21%) diagnosed in early childhood. New onset of seizures was the most common presenting symptom, leading to diagnosis in 27 cases, including 1 in which seizures were observed during a sleep study for night terrors. History of seizures led to diagnosis in 12 children, including 1 with a history of infantile spasms and partial onset of seizures. Dermatologic features were also common presenting signs.
In 7 children, developmental delay was observed by parents or physicians before TSC diagnosis. Four children had previously noted cardiac rhabdomyomas. In 3, rhabdomyomas were observed prenatally or at birth, but those children did not initially meet sufficient criteria for diagnosis. In the fourth, cardiac rhabdomyoma was seen on a chest radiograph at the age of 2 in the setting of an upper respiratory infection, but it is unclear why diagnosis of TSC was delayed for another 2.5 years.
Late Childhood: 6 to 10 Years
There were 23 patients (10%) diagnosed in late childhood, most com- Cases of earlier missed symptoms or signs included 6 patients with developmental delay and 1 with infantile spasms. One child with developmental delay was diagnosed with cerebral palsy until the appearance of dermatologic features at the age of 8.
Adolescence: 11 to 20 Years
There were 16 patients (7%) diagnosed in adolescence. The most common presenting symptoms and signs were new onset of seizures and angiofibromas. In 1 case, seizures were first observed in the setting of psychiatric hospitalization. In 3 patients, neurologic manifestations of TSC were seen on MRI during evaluation for other neurologic symptoms: headaches; hemiparesis; and increased intracranial pressure.
Missed earlier symptoms and signs were not uncommon in this age group. One patient had seizures until the age of 5 and was not diagnosed with TSC until epilepsy reemerged at the age of 17. In another, cortical tubers and subependymal nodules were noted on MRI in the setting of seizures, but he was not evaluated for TSC until his mother was diagnosed 5 years later. Two patients reported a history of migraines before diagnosis.
Adulthood: 21 Years and Older
There were 30 patients (12%) diagnosed in adulthood. They were most likely to present for diagnostic evalua- (43) 5 (11) 7 (16) 1 (2) 1 (2) Numbers in presenting symptom columns will not add up to the total numbers of patients in each genotype group because many patients had more than 1 presenting symptom, and all presenting symptoms were counted. when onset occurred in adulthood. The latest observed onset of seizures was in a 45-year-old woman who had no other symptomatic or cutaneous manifestations.
Earlier Missed Symptoms or Signs
There were 95 patients (39%) in which earlier-reported manifestations of TSC did not lead to diagnosis. Of these, 24 had 2 or more symptoms or signs.
Seizures (including new onset, history of seizures, and infantile spasms) were the most commonly missed earlier symptom of TSC and were noted in 46 (19%) patients. In these cases, seizures were treated for periods of time that ranged from 6 weeks to 36 years before TSC diagnosis.
Infantile spasms preceded TSC diagnosis in 15 (6%) cases. In 9, spasms were diagnosed at onset. In 1, spasms were not recognized until 4 months after onset. In 5, spasms were not initially diagnosed, but were retrospectively characterized as such years later.
Dermatologic features did not lead to TSC diagnosis in 22 (9%) patients and were frequently present with other signs of TSC. Developmental delay had been noted in 16 of these patients, 1 of whom was diagnosed with cerebral palsy until the appearance of angiofibromas in late childhood. Other missed earlier signs included cardiac rhabdomyoma, renal angiomyolipoma, family history of TSC, SGCT, and multifocal micronodular pneumocyte hyperplasia.
DISCUSSION
Genetically tested patients with a TSC2 mutation were diagnosed, on average, 9 years before patients with a TSC1 mutation and 11 years before those with no mutation identified (NMI). Earlier diagnosis of patients with TSC2 mutation may have been a result of the associated phenotype, which generally includes a greater number and severity of symptoms than phenotypes associated with TSC1 mutation and NMI. 4, 18 Patients with a TSC2 mutation were more likely to present with infantile spasms, developmental delay, or angiofibromas than were patients with a TSC1 mutation or NMI. Patients with a TSC1 mutation were more likely to present with a family history of TSC or hypopigmented macules than were patients with TSC2 mutation or NMI, and were less likely to present with cardiac rhabdomyomas. Patients with NMI were more likely to present with renal angiomyolipomas than those with identified mutations. The only case of presentation with lymphangioleiomyomatosis was a patient with NMI.
Disease-causing mutations have been identified in patients with TSC before appearance of symptoms. Diagnostic criteria of TSC should be revised to include disease-causing mutations. 19 Genetic testing can facilitate early diagnosis, especially in patients with a family history of TSC. However, because mutations cannot be identified in ϳ15% of TSC cases, 5 lack of identifiable mutation should not preclude additional investigation for TSC. Patients with NMI may be more likely to have certain symptoms, such as lymphangioleiomyomatosis, 20 which requires careful monitoring.
A previous study of 73 patients with TSC demonstrated that 25% were not diagnosed after first appearance of symptoms. 21 In this study, 95 records (39%) reported earlier symptoms or signs that were missed. Seizures were the most commonly missed symptom, and were noted in 19% of patients.
Although seizures were the most commonly missed symptom, seizures (other than infantile spasms) were also the most common presenting symptom (47%). This finding is slightly lower than that of a previous study, 18 but the authors did not differentiate between seizures and infantile spasms. Both studies suggest that seizures are the most common presenting symptom of TSC. 22 Patients with TSC have an 84% lifetime risk of seizures, which typically begin early in life 15 and may change in semiology with age. 11, 23 Prenatal seizures 15 and onset of epilepsy in adolescence 18 and adulthood 15 Infantile spasms are a common presenting symptom of TSC, 25 and 13% of patients in this study were diagnosed because of their emergence. Infantile spasms are generalized myoclonic seizures typically characterized by hypsarrhythmia on EEG. They are seen in one-third to two-thirds of children with TSC. 11, 20 In some series, 20% to 25% of cases of infantile spasms are associated with TSC. 26 Infantile spasms may precede, follow, or coexist with other types of seizures, and often begin between 4 and 6 months of age. 19 The earliest case of infantile spasms in this study was diagnosed at the age of 2 months, but parents reported onset at a few weeks after birth. The latest reported onset was at 10 months. Infantile spasms are a risk factor for poor cognitive development in TSC. 27 Immediate identification and treatment are necessary to reduce seizure frequency 28 and risk of cognitive impairment. 29 Cardiac rhabdomyomas were a presenting sign in 12% of all patients, and in 30% of patients who were diagnosed before the age of 6 months. Prenatal cardiac rhabdomyomas are frequently the first detectable manifestation of TSC, 30 and were found in all patients diagnosed during the first week of life. The 3 patients who presented with rhabdomyomas (either prenatally or at birth) but did not initially meet diagnostic criteria demonstrate the importance of continued monitoring in children with suspected TSC. A comprehensive care plan can address the potential emergence of more serious complications, such as seizures.
Dermatologic features of TSC can be easily recognizable, and are present in 96% of patients with TSC. 31 In this study, dermatologic features were common presenting signs, but were also missed in 9% of patients. Presentation of dermatologic features is agedependent. Hypopigmented macules, which may serve as first evidence of TSC, 32 were a common presenting sign in infants and young children. Angiofibromas and periungual fibromas were more likely to lead to diagnosis in adolescence and adulthood. Angiofibromas do not typically appear before the age of 3 or 4, 7 but may grow rapidly during puberty. 30 Family history of TSC often played a role in the diagnosis of our patients. However, because approximately twothirds of cases of TSC arise spontaneously, 5 a negative family history should not preclude additional investigation for TSC.
It is recommended that patients with epilepsy, developmental delay, or a learning disability are investigated for TSC in the absence of other known etiology because of the high number of patients with TSC presenting with these symptoms. 18 Our results support this recommendation.
This study is limited because data were collected retrospectively; therefore, some information may be incomplete. Our findings of earlier missed symptoms or signs of TSC may represent an underestimate, as earlier symptoms or signs may not be well documented.
CONCLUSIONS
It is not uncommon for patients with TSC to have symptoms or signs that do not lead to immediate diagnosis. In some cases, diagnosis is delayed for prolonged periods of time. Symptoms and signs of TSC may be diagnosed incorrectly, or incorrectly lead to diagnosis of other disorder or illness. Clinicians, including child and adult neurologists, dermatologists, nephrologists, and cardiologists, should be aware of the myriad potential presenting symptoms and signs of TSC. Early diagnosis is important for thorough clinical and radiologic evaluation, continuous monitoring of symptoms, family planning, genetic counseling, and reduction of morbidity and mortality.
Ongoing clinical trials of the drug rapamycin have demonstrated efficacy in reducing symptoms of TSC. 10 Early diagnosis could be especially beneficial to patients if preventive treatment becomes available.
